Lung cancer soft meningeal metastasis marker and application thereof

By detecting specific biomarkers in cerebrospinal fluid and constructing machine learning models, the diagnostic challenge of leptomeningeal metastasis has been solved, improving the diagnostic accuracy and sensitivity of leptomeningeal metastasis in solid tumors such as lung cancer, and providing a more reliable diagnostic tool.

CN121528501APending Publication Date: 2026-02-13THE SECOND HOSPITAL OF DALIAN MEDICAL UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202511731380.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-11-24
Publication Date
2026-02-13

AI Technical Summary

Technical Problem

Current technologies are insufficient for effectively diagnosing and monitoring leptomeningeal metastases, especially those caused by solid tumors such as lung cancer, breast cancer, gastric cancer, and melanoma, leading to difficulties in clinical diagnosis and complex treatment options.

Method used

Using biomarkers such as Hydroxyphenyllactic acid, Betaine, 3-Methoxytyrosine, L-Kynurenine, 1-Methylguanosine, and 2-Hydroxyethanesulfonate, combined with targeted or non-targeted techniques such as nuclear magnetic resonance, chromatography, spectroscopy, and mass spectrometry, a machine learning algorithm diagnostic model was constructed to diagnose leptomeningeal metastasis by detecting the biomarker levels in cerebrospinal fluid samples.

Benefits of technology

It has improved the diagnostic accuracy and sensitivity of leptomeningeal metastasis, especially the diagnostic efficacy of lung cancer leptomeningeal metastasis, provided more reliable diagnostic tools and methods, and reduced the risk of misdiagnosis.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a lung cancer soft meningeal metastasis marker and application thereof. The marker for the soft meningeal metastasis of the lung cancer comprises one or more of Hydroxyphenylic acid, Betaine, 3-Methoxytyrosine, L-Kyninuine, 1-Methoxyguanosine and 2-Hydroxyphenylethanosine, and whether a subject suffers from the soft meningeal metastasis of the lung cancer or is suspected to suffer from the soft meningeal metastasis of the lung cancer or not can be diagnosed by detecting the level of the marker in a sample of the subject. The invention has a good application prospect in diagnosis of lung cancer soft meningeal metastasis.
Need to check novelty before this filing date? Find Prior Art